HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)
Conditions
Brief summary
The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.
Interventions
DRUGCHOP-daclizumab
Sponsors
King's College Hospital NHS Trust
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed ATLL requiring treatment 1. Frank acute leukaemia or lymphoma subtypes 2. Chronic and smouldering cases should be considered if they are symptomatic and require therapy, or there is evidence of disease progression 2. No previous treatment with anthracycline based cytotoxic chemotherapy a. Patients may have received interferon and /or zidovudine and/or non-anthracycline based therapy 3. Age 18-75 years 4. Written informed consent
Exclusion criteria
1. HIV 1 or 2 positivity 2. Pregnancy or breast-feeding 3. Concomitant chemo-radiotherapy 4. Prior hepatic or renal insufficiency with a bilirubin or transaminases greater than 5 times the normal range or a creatinine greater than 150μmol/l (not related to hypercalcaemia) following rehydration 5. Other concomitant neoplasms not related to HTLV-I 6. Cardiac or respiratory insufficiency with an ECOG score of greater than 3 7. Any serious active uncontrolled infection
Countries
United Kingdom
Outcome results
None listed